In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance

Antiviral Research

Volumn 120, Issue 1, 2015, Pages 112-121

  Vliegen, Inge ^a   Paeshuyse, Jan ^a   Zhong, Weidong ^b,c   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b GILEAD SCIENCES   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Cell curing; Combination therapy; DAA; HCV; Resistance development; Tegobuvir

Indexed keywords

2' METHYLCYTIDINE; 5 [[3 (4 CHLOROPHENYL) 5 ISOXAZOLYL]METHYL] 2 (2,3 DIFLUOROPHENYL) 5H IMIDAZO[4,5 C]PYRIDINE; ANTIBIOTIC G 418; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; JT 16; NESBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TEGOBUVIR; TELAPREVIR; THIOPHENE CARBOXYLIC ACID; UNCLASSIFIED DRUG; ALPHA INTERFERON; OLIGOPEPTIDE; PURINE DERIVATIVE; PYRIDAZINE DERIVATIVE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CC50; CELL PROLIFERATION; DRUG EFFICACY; DRUG POTENTIATION; EC50; GENOTYPE; HEPATITIS C VIRUS GENOTYPE 1; HEPATOMA CELL; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPLICON CELL; RNA ANALYSIS; VIRAL CLEARANCE; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HUMAN; LIVER CELL; VIROLOGY;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; PURINES; PYRIDAZINES; RIBAVIRIN; RNA, VIRAL;

EID: 84934905696     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.05.011     Document Type: Article

References (27)

1. Asselah, T., Marcellin, P., 2012. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int. 32, 88-102.
2. Bae, A., Jackson, J., Ku, K., Harris, J., Miller, M., Borroto-Esoda, K., et al., 2010. Sensitive detection of Y448H NS5B mutant virus in patients infected with genotype 1a and 1b HCV. Hepatology 52 (S1), 1223A.
3. Bondy, S.S., Dowdy, E.D., Kim, C.U., Oare, D.A., Neyts, J., Zia, V., et al., inventors; 2005. Imidazo 4,5-C pyridine compounds and methods of antiviral treatment.WO2005/063744. 2005 Jul 14.
4. Bondy, S.S., Dowdy, E.D., Kim, C.U., Oare, D.A., Neyts, J., Zia, V., et al., inventors; 2007. Imidazo 4,5-C pyridine compounds and methods of antiviral treatment.US 2007/02441148. 2007 Oct 18.
5. Bondy, S.S., Dahl, T.C., Oare, D.A., Oliyai, R., Tse, W.C., Zia, V., inventors; 2008a. Novel pyridazine compound and use thereof.US 2008/0199427 A1. 2008, Aug 21.
6. Bondy, S.S., Dahl, T.C., Oare, D.A., Oliyai, R., Tse, W.C., Zia, V., inventors; 2008b. Novel pyridazine compound and use thereof.WO 2008/005519. 2008, Jan 10.
7. Delang, L., Paeshuyse, J., Vliegen, I., Leyssen, P., Obeid, S., Durantel, D., et al., 2009. Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology 50, 6-16.
8. Delang, L., Vliegen, I., Froeyen, M., Neyts, J., 2011. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob. Agents Chemother. 55, 4103-4113.
9. Delang, L., Froeyen, M., Herdewijn, P., Neyts, J., 2012. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. Antiviral Res. 93, 30-38.
10. Foster, G.R., Buggisch, P., Marcellin, P., Zeuzem, S., Agarwal, K., Manns, M., et al., 2011. Four-week treatment with GS-9256 and Tegobuvir (GS-9190), +/-RBV +/-PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients. J. Hepatol. 54, S172.
11. Gane, E.J., Roberts, S.K., Stedman, C., Angus, P.W., Ritchie, B., Elston, R., et al., 2009. First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ITMN191) inhibitor combination in HCV: safety, pharmacokinetics, and virologic results from INFORM-1. J. Hepatol. 50, S380.
12. Hebner, C., Harris, J., Oldach, D., Miller, M.D., Mo, H., 2011. Emergence and persistence of NS5B mutations following combination treatment with Tegobuvir (GS-9190) plus standard of care-long-term follow-up from the phase IIB study GS-US-196-0103. J. Hepatol. 54, S478-S479.
13. Hebner, C.M., Han, B., Brendza, K.M., Nash, M., Sulfab, M., Tian, Y., et al., 2012. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 7, e39163.
14. Lawitz, E., Jacobson, I., Godofsky, E., Foster, G.R., Flisiak, R., Bennett, M., et al., 2011. A Phase 2B trial comparing 24 to 48 weeks treatment with Tegobuvir (GS-9190)/PEG/RBV to 48 weeks treatment with PEG/RBV for chronic genotype 1 HCV infection. J. Hepatol. 54, S181.
15. Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
16. Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., et al., 2012. Preliminary study of two antiviral agents for hepatitis C genotype 1. N. Engl. J. Med. 366, 216-224.
17. Manns, M.P., Wedemeyer, H., Cornberg, M., 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350-1359.
18. Paeshuyse, J., Vliegen, I., Coelmont, L., Leyssen, P., Tabarrini, O., Herdewijn, P., et al., 2008. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. Antimicrob. Agents Chemother. 52, 3433-3437.
19. Prichard, M.N., Shipman Jr., C., 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14, 181-205.
20. Sarrazin, C., Kieffer, T.L., Bartels, D., Hanzelka, B., Muh, U., Welker, M., et al., 2007. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777.
21. Sarrazin, C., Hezode, C., Zeuzem, S., Pawlotsky, J.M., 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56 (Suppl. 1), S88-100.
22. Shih, I.H., Vliegen, I., Peng, B., Yang, H., Hebner, C., Paeshuyse, J., et al., 2011. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55, 4196-4203.
23. Sulkowski, M., Rodriguez-Torres, M., Lawitz, E., Shiffman, M., Pol, S., Herring, R., et al., 2012. High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results. J. Hepatol. 56, S560.
24. Vliegen, I., Paeshuyse, J., De Burghgraeve, T., Lehman, L.S., Paulson, M., Shih, I.H., et al., 2009. Substituted imidazopyridines as potent inhibitors of HCV replication. J. Hepatol. 50, 999-1009.
25. Vrolijk, J.M., Kaul, A., Hansen, B.E., Lohmann, V., Haagmans, B.L., Schalm, S.W., et al., 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110, 201-209.
26. Windisch, M.P., Frese, M., Kaul, A., Trippler, M., Lohmann, V., Bartenschlager, R., 2005. Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line. J. Virol. 79, 13778-13793.
27. Zeuzem, S., Buggisch, P., Agarwal, K., Marcellin, P., Sereni, D., Klinker, H., et al., 2012. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55, 749-758.